Viewpoint: The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?

xie, feihu chinese academy of medical sciences - peking union medical college hospital - department of liver surgery, Beijing, China , feng, shi chinese academy of medical sciences - peking union medical college hospital - department of liver surgery, Beijing, China , sun, lejia chinese academy of medical sciences - peking union medical college hospital - department of liver surgery, Beijing, China , mao, yilei chinese academy of medical sciences - peking union medical college hospital - department of liver surgery, Beijing, China

2654465